Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Protagonist Therapeutics (PTGX) Stock Price & Analysis
559 Followers
PTGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.72 - $33.34
Previous Close$28.23
Volume541.03K
Average Volume (3M)554.32K
Market Cap
$1.66B
Enterprise Value$1.32B
Total Cash (Recent Filing)$341.63M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)11.5
Beta0.77
Next Earnings
Aug 01, 2024EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.45
Shares Outstanding58,652,133
10 Day Avg. Volume519,527
30 Day Avg. Volume554,318
Standard Deviation0.29
R-Squared0.14
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.92
Price to Sales (P/S)28.66
Price to Cash Flow (P/CF)24.40
P/FCF Ratio24.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.92
Enterprise Value/Gross Profit21.92
Enterprise Value/Ebitda-16.40
Forecast
1Y Price Target
$41.80Price Target Upside42.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Protagonist Therapeutics News
PremiumStock Analysis & Ideas
3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts Ownership Overview
5.55% Insiders
13.95% Mutual Funds
28.99% Other Institutional Investors
51.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $13.72 and its highest was $33.34 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Currently, no data Available
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 79 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on May 08, 2024. The company reported $3.26 earnings per share for the quarter, missing the consensus estimate of $3.367 by -$0.107.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -$0.6.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 58,652,134 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of $3.26 in its last earnings report, missing expectations of $3.367. Following the earnings report the stock price went up 4.279%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 131M.
---
Protagonist Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.80 (42.56% Upside)
$41.80 (42.56% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 180.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $783.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.82%
12-Months-Change
Fundamentals
Return on Equity
41.75%
Trailing 12-Months
Asset Growth
162.35%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PTGX Stock 12 Month Forecast
Average Price Target
$41.80
▲(42.56% Upside)
Technical Analysis
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+52.31%
reiterated a buy rating 7 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +52.31% per trade.
---